Ask AI · Why did Kelun Pharmaceutical choose the anesthesia field as the breakthrough for innovation?

On April 3rd, Kelun Pharmaceutical disclosed key progress in innovative drug R&D during an institutional survey, marking the company’s transition from a traditional large infusion giant to an innovative drug company entering a substantive implementation stage.

Deepening Innovation

Kelun Drug Research Institute’s first Class 1 innovative drug focuses on the anesthesia field, has been approved for clinical trials, and entered dose escalation phase, representing a critical breakthrough from zero to one in the company’s independent small-molecule innovation.

This drug targets unmet clinical needs for sedation and anesthesia, leveraging the company’s long-term accumulated R&D capabilities and clinical resources in anesthesia. From target discovery, molecular design to clinical application, the entire process is independently controllable, filling a gap in the company’s Class 1 innovative small-molecule portfolio and validating Kelun’s R&D strength in high-barrier fields, laying a solid foundation for continuous pipeline output.

The preclinical (PCC) pipeline is strategically focused on two high-barrier tracks: central nervous system (CNS) and antifungal infections. Projects for schizophrenia and depression have completed PCC screening; antifungal drugs are progressing faster and have also entered the PCC stage simultaneously.

The company has clarified that future project approvals will fully revolve around the two core areas of CNS and endocrinology, moving away from the “broad net” imitation drug model toward high-value, high-technology barrier differentiated innovation.

This pipeline layout is not a single point breakthrough but a concentrated embodiment of Kelun’s “imitate-innovate integration” strategy.

As a traditional strength, anesthesia is a key track for the company. Upgrading from generic drugs to Class 1 innovative drugs, it relies on existing channels and clinical resources, making R&D risks relatively manageable.

In CNS and antifungal fields, the company precisely targets unmet clinical needs, actively avoiding the highly competitive “red ocean” tracks like oncology and glucose-lowering drugs prevalent in the domestic innovation market, choosing segments with higher R&D difficulty, better competitive landscape, and more long-term value.

Through a tiered layout of “clinical stage validation + preclinical reserves,” the company achieves orderly advancement of its innovative pipeline, continuing its long-term accumulated R&D experience, clinical resources, and channel advantages in anesthesia, while preemptively deploying in high-barrier tracks to open broader future growth space. This fully demonstrates Kelun’s R&D strategy evolution from “broad net” to “precise deep cultivation.”

Supply and Demand Imbalance

From an industry perspective, the fields of anesthesia, CNS, antifungal, and endocrinology that Kelun is deploying are in a “rigid demand + scarce supply” golden cycle. Domestic substitution space is broad, and R&D barriers naturally create a protective moat.

The anesthesia market benefits from the popularization of comfortable medical care. In 2024, the domestic market size is about 38.5 billion yuan. The expansion of scenarios such as painless childbirth, endoscopic diagnosis and treatment, and medical aesthetics drives continuous demand growth. However, high-end sedatives still rely on imports, and domestic innovative drugs have clear substitution potential.

As the second-largest pharmaceutical market globally, the CNS sector’s domestic scale approaches 100 billion yuan. Over 100 million patients suffer from depression and schizophrenia, with diagnosis rates below 30%. Existing drugs face efficacy limitations and significant side effects, and R&D barriers are extremely high (difficult blood-brain barrier penetration, clinical failure rate over 90%). It has long been monopolized by foreign giants like Pfizer and Lilly, making it a timely opportunity for domestic companies to break through.

The antifungal track, though smaller than CNS, has significant unmet needs. Invasive fungal infections have high mortality rates, especially in ICU and oncology chemotherapy scenarios. The high-end market is dominated by Pfizer and Merck, with a scarcity of domestic innovative options.

The endocrinology field (diabetes, obesity, etc.) is a global hot track. Drugs like GLP-1 are driving market structural expansion, and unmet needs continue to be released.

In reality, China’s innovative drug industry has moved away from “Me-too” internal competition toward “clinical value-oriented” development. Companies focusing on high-barrier niche areas will gain long-term competitive advantages.

Dual-Drive Strategy

Kelun’s transformation is not an illusion but relies on the fundamentals of “stable traditional business + rapid innovation,” forming a “generic drug cash flow + innovative drug growth pole” dual-gear pattern, with risk resistance far surpassing pure R&D biotech firms.

On the traditional business side, as a leading domestic infusion company, Kelun’s infusion segment has bottomed out and rebounded. Coupled with scaled deployment of Sichuan Nanning Biological’s antibiotics intermediates and synthetic biology businesses (e.g., red myrrh alcohol, ergothioneine), it provides stable cash flow supporting over 2 billion yuan annually in R&D investment.

By 2025, the company’s revenue is expected to exceed 18.5 billion yuan, with net profit around 1.7 billion yuan, and ROE above industry average, with ample funds to secure innovation R&D.

Meanwhile, the company already has mature generic drug layouts in CNS and anesthesia, with products like oxcarbazepine tablets and bupivacaine liposomes accumulating hospital channel resources, paving the way for subsequent drug commercialization.

In innovation, Kelun has formed a synergistic layout of “Kelun Botai’s large molecules + Drug Research Institute’s small molecules.”

Its subsidiary Kelun Botai’s ADC drug (SKB264) has been launched and included in medical insurance, becoming a cash cow for innovative drugs and validating the company’s commercialization capability.

The advancement of its independent small-molecule pipeline fills a gap in the company’s innovation in anesthesia, CNS, and other fields, complementing existing generics and building a “combination of innovation + imitation” full product matrix.

In terms of R&D capability, the first Class 1 new drug has entered dose escalation, and PCC projects are continuously landing, demonstrating that Kelun Drug Research Institute has established a complete system from molecule screening to clinical progression, significantly improving R&D maturity.

R&D Testing Patience

Kelun’s pipeline strategy upgrade essentially redefines the company’s valuation from a “manufacturing-oriented” to a “R&D-oriented” pharmaceutical company, containing multiple growth logic. However, the high risk and long cycle nature of innovative drug R&D must be carefully considered.

From value and opportunity perspectives, high barriers in the tracks bring profit upgrades. The anesthesia, CNS, and endocrinology tracks all have gross margins exceeding 80%. If the pipelines progress smoothly, they could fundamentally change the company’s profit structure from reliance on low-margin infusions.

Under the monopoly of foreign capital, Kelun, leveraging cost and channel advantages, is expected to quickly capture market share after innovative drug approval, releasing domestic substitution dividends.

Clinical-stage anesthesia drugs and preclinical CNS and antifungal projects are linked, with short-term clinical progress catalyzing valuation, and long-term track space supporting growth. The valuation system may shift from a cyclical stock to an innovative drug valuation.

However, risks are also significant. The success rate for CNS and antifungal drugs in clinical trials is less than 10%. From PCC to market, it takes 8-10 years, with the risk of huge investments going to waste.

All pipelines are in early stages, unlikely to contribute to performance in the short term, and sustained high R&D investment may drag down profits.

The CNS track faces strong competitors like Hengrui and Enhua; in endocrinology, competition from blockbuster drugs like GLP-1 is intense. As a latecomer, Kelun needs to outperform in clinical data and commercialization speed.

Procurement pressures may impact drug pricing, and anesthesia drugs are strictly regulated by the government, with uncertainties in approval and sales processes.

Kelun is at a critical window of transformation. The clinical advancement of new anesthesia drugs is a key milestone, and the layout in CNS and endocrinology opens long-term growth space.

Innovative drug R&D is a long-distance marathon. With a solid traditional business foundation and differentiated innovation pipeline, Kelun has the potential to traverse cycles. However, subsequent clinical progress and R&D efficiency will be key to validating its value. Investors should view this transformation with patience.

Attention: This article is based on publicly available information or interviews. The author does not guarantee the completeness or accuracy of the information. Under no circumstances does this content constitute investment advice. Market risks exist; invest cautiously! Reproduction or plagiarism without permission is prohibited!